STRO-1+ Cell Therapy for Post-Stroke Neuron Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke primarily focus on mitigating ongoing neurological damage and do not effectively restore lost brain function or neurons, with existing neuroprotective agents showing limited efficacy.
Innovation Solution
Administration of a population of STRO-1 +< cells, enriched for non-hematopoietic multipotential cells, which can be derived from bone marrow or dental pulp, to promote neuroprotection, angiogenesis, immune-modulation, and neuroplasticity, and potentially differentiate into neuronal-like cells, thereby restoring cerebral function and regenerating neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current stroke treatments (aspirin, thrombolysis, hemicraniectomy) are used to mitigate ongoing neurological damage, then intracranial pressure is reduced and further stroke is prevented, but lost neurons and brain function are not restored
Solution Approach 1:
The patent uses bone marrow-derived mononuclear cells as intermediary agents to mediate between the damaged brain tissue and the body's regenerative capacity. These cells migrate to the stroke site and facilitate neuronal restoration through multiple mechanisms including neuroprotection, angiogenesis, and differentiation into neuronal-like cells, thereby bridging the gap between damage mitigation and functional restoration
Solution Approach 2:
The patent employs the patient's own bone marrow cells (autologous transplantation) to restore lost brain function. The patient's body self-generates the therapeutic cells through bone marrow aspiration and culture expansion, eliminating the need for external cell sources and enabling self-repair of neurological damage
2Reliability
If neuroprotective agents (NMDA receptor antagonists, calcium channel blockers, etc.) are administered to protect neurons, then ongoing neurological damage is reduced, but lost neurons are not regenerated
Solution Approach 1:
The patent changes the fundamental parameter of treatment from pharmacological neuroprotection to cellular therapy. Instead of using chemicals to prevent damage, the invention introduces living bone marrow-derived mononuclear cells that can dynamically respond to the injury environment, migrate to affected areas, and actively participate in tissue repair and regeneration processes
Solution Approach 2:
The patent creates a composite therapeutic approach by combining bone marrow-derived mononuclear cells with culture expansion techniques. The cells are harvested, expanded in vitro to increase cell numbers, and then retrans implanted, creating a composite therapy that leverages both the regenerative potential of stem cells and the amplification power of cellular culture
3Reliability
If stem cell transplantation is performed in immunosuppressed patients, then cell survival and engraftment are improved, but the treatment complexity and cost increase
Solution Approach 1:
The patent uses autologous bone marrow-derived mononuclear cells from the same patient, eliminating the need for immunosuppression protocols. The patient's own cells are harvested, cultured, and retrans implanted, avoiding immune rejection without requiring complex immunosuppressive medication regimens or matched donor searches
Solution Approach 2:
The patent performs preliminary culture expansion of the bone marrow cells before transplantation. This preliminary action increases the cell numbers to ensure adequate engraftment and therapeutic effect, while the autologous nature of the cells eliminates the need for subsequent immunosuppression, simplifying the overall treatment protocol
Data Source
Figure 1
Figure 2a
Figure 2c
AI summary
The present disclosure provides methods of improving cerebral function or preventing loss of cerebral function and/or treating or preventing a movement disorder and/or regenerating cerebral neurons in a subject who has suffered a stroke, the method comprising administering to the subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.